AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Video

In Partnership With:

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Related Videos
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Núria Agustí Garcia, MD
Stephen V. Liu, MD
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Related Content
Andrew Joe, MD

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
Yuankai Shi, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024
Article
John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024
Podcast
Nicolas Girard, MD, PhD, of Curie-Montsouris Thorax Institute

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

April 26th 2024
Article
Raj Singh, MD, of The Ohio State University Comprehensive Cancer Center––James

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024
Article